Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Jefferies Financial Group began coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) in a report issued on Friday, The Fly reports. The brokerage issued a buy rating on the stock. Other equities analysts have also issued research reports about the company. William Blair lowered Praxis Precision Medicines from an outperform rating to […]
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider. | May 11, 2023
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 5,970,000 shares, an increase of 34.2% from the March 15th total of 4,450,000 shares. Approximately 14.4% of the company’s shares are sold short. […]
HC Wainwright reiterated their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) in a research report sent to investors on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock. Separately, William Blair lowered shares of Praxis Precision Medicines from an outperform rating to a market […]